ArticleEuropean clinical respiratory journal2026
Characteristics of severe asthma patients with biologic treatment in the Swedish National Airway Register.
Article in European clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Swedish National Airway Register (SNAR) includes data on asthma control, lung function, biomarkers, treatments, and comorbidities from asthma patients in primary and secondary care. This study aimed to describe patients with severe asthma receiving biologic treatment in SNAR and to explore its potential as a national registry for severe asthma. Methods: Patients with ongoing treatment with mepolizumab, benralizumab, reslizumab, dupilumab or tezepelumab and registered in SNAR between 2016 and 2024 were included. Demographic characteristics, asthma treatment, asthma control, lung function, type 2 biomarkers, and exacerbation history were described. Data were assessed at inclusion and at the most recent follow-up available. Results: A total of 416 patients were identified; 49% were female, mean age was 54.1 years, and mean BMI was 27.2. Inhaled corticosteroids were used by 94.4% of patients, while 39.2% received maintenance oral corticosteroids at inclusion. Asthma control was generally low and exacerbations were common. Patients differed across biologic classes with respect to age, comorbidities, lung function and biomarker profiles, reflecting heterogeneity. At follow-up (mean 193 days), improvements were observed in asthma control, lung function, type 2 biomarkers, and exacerbation frequency. Marked geographic variation in registry inclusion was identified, with several regions reporting no patients. Conclusion: SNAR enables nationwide characterization of patients with severe asthma treated with biologics in routine care. However, variation in inclusion and follow-up limits longitudinal interpretation. More standardized registration, particularly at treatment initiation, would strengthen SNAR's role in national monitoring, quality improvement and future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.